-

Survey Finds Pharma Execs Uncertain About How COVID-19 Will Affect the Volume of Business Development Efforts

Depression of Valuations and Potential Need for Cash May Create Climate for Deals for Agile New Product Planning and Business Development Teams, According to a New Brief from Trinity Life Sciences

WALTHAM, Mass.--(BUSINESS WIRE)--Trinity Life Sciences, a leader in global life sciences solutions, finds that New Product Planning (NPP) pharmaceutical executives are uncertain about how COVID-19 will affect the volume of business development efforts. According to the new brief entitled Impact of COVID-19 on New Product Planning, NPP teams are mixed in their expectations for the volume of business development (BD) efforts to change in the near term due to the COVID-19 outbreak.

“NPP teams are seeking ways to overcome delays in clinical development and may be looking to BD as a way to fill that gap,” said Leslie Orne, Senior Partner and Chief Client Officer at Trinity. “Some respondents also thought depression of valuations and potential need for cash may create a climate of more deals in the wake of COVID-19, and NPP/BD groups should be ready to move quickly.”

The brief was based on a survey of NPP pharma leaders focusing on how they are approaching the challenges and uncertainty caused by COVID-19. The brief also finds that although NPP teams anticipate delays in market research as they shift to virtual methods, they may find healthcare providers’ availability to be better than they expect, enabling them to continue critical research and strategic decision-making in the near term.

For a full copy of Impact of COVID-19 on New Product Planning, please visit www.TrinityLifeSciences.com.

About Trinity Life Sciences
Trinity Life Sciences is a trusted strategic partner, providing evidence-based solutions for the life sciences. With over 20 years of experience, Trinity is committed to solving clients’ most challenging problems through exceptional levels of service, powerful tools, and data-driven insights. Trinity’s range of products and solutions includes industry-leading benchmarking solutions, powered by TGaS Advisors. To learn more about how Trinity is elevating life sciences and driving evidence to action, visit trinitylifesciences.com.

Contacts

Elizabeth Marshall
Trinity Life Sciences
781-577-6376
emarshall@trinitylifesciences.com

Trinity Life Sciences


Release Versions

Contacts

Elizabeth Marshall
Trinity Life Sciences
781-577-6376
emarshall@trinitylifesciences.com

More News From Trinity Life Sciences

Trinity Appoints Scott Evangelista as CEO to Lead Next Chapter

WALTHAM, Mass.--(BUSINESS WIRE)--Trinity, a global leader in technology-enabled commercialization solutions for the life sciences industry, today announced Scott Evangelista has been appointed Chief Executive Officer, succeeding Leslie Orne who is stepping down after three years as CEO and over 24 years with the company. Ms. Orne will transition to the role of Senior Advisor and serve as a member of Trinity’s Board of Directors. Over her distinguished tenure, Ms. Orne helped guide Trinity’s evo...

GSK, Amgen and AstraZeneca Lead the Pack in Trinity’s 2025 Digital Marketing Competency Report

WALTHAM, Mass.--(BUSINESS WIRE)--Trinity, a leader in global life sciences commercialization, today announced the release of its 5th Annual TGaS Digital Marketing Competency Report, a three-part series benchmarking the digital marketing presence of more than 150 biopharma brands. The 2025 edition reveals a significant leap forward in the industry’s digital sophistication, with a 19% increase in Proficient brands and a surge of innovation in patient engagement strategies. The report ranks each b...

Trinity Expands Global Footprint with Acquisition of EVERSANA’s APACME Advisory Services

WALTHAM, Mass.--(BUSINESS WIRE)--Trinity, a leader in global life sciences commercialization solutions and recognized for being a strategic, tech-enabled commercialization company that empowers pharma, biotech, and medtech organizations to advance medical innovations, announced today the acquisition of EVERSANA’s advisory services operation in Asia-Pacific and the Middle East (APACME). The strategic acquisition will transition EVERSANA’s advisory services operation in APACME to Trinity, further...
Back to Newsroom